Home » Stocks » MESO

Mesoblast Limited (MESO)

Stock Price: $7.16 USD -0.10 (-1.38%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 934.53M
Revenue (ttm) 6.16M
Net Income (ttm) -109.36M
Shares Out 129.48M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE 454.55
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $7.16
Previous Close $7.26
Change ($) -0.10
Change (%) -1.38%
Day's Open 7.18
Day's Range 7.11 - 7.26
Day's Volume 66,694
52-Week Range 6.67 - 21.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Mesoblast Limited (NASDAQ: MESO) has announced the presentation of 90-day survival outcomes from the remestemcel-L trial in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory ...

1 week ago - Benzinga

NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from th...

1 week ago - GlobeNewsWire

NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the...

1 week ago - GlobeNewsWire

Mesoblast Limited (NASDAQ: MESO) provided an update on the strategy for bringing rexlemestrocel-L to patients in the U.S. with chronic low back pain (CLBP) due to degenerative disc disease refractory to...

3 weeks ago - Benzinga

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy f...

3 weeks ago - GlobeNewsWire

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and ...

1 month ago - GlobeNewsWire

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss opera...

1 month ago - GlobeNewsWire

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed jour...

2 months ago - GlobeNewsWire

Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down...

2 months ago - Zacks Investment Research

The company announced positive results from a clinical trial.

2 months ago - The Motley Fool

Mesoblast Limited (NASDAQ: MESO) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS), ...

2 months ago - Benzinga

Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021 Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021

2 months ago - GlobeNewsWire

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from t...

2 months ago - GlobeNewsWire

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a co...

2 months ago - GlobeNewsWire

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Company...

3 months ago - GlobeNewsWire

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completion...

4 months ago - GlobeNewsWire

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics (Journal o...

5 months ago - GlobeNewsWire

One of its pipeline candidates achieved great results in a late-stage clinical study.

5 months ago - The Motley Fool

Positive results from Mesoblast Limited's (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the company's shares higher in the premarket after an announcement sho...

5 months ago - Benzinga

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase 3 r...

5 months ago - GlobeNewsWire

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline o...

5 months ago - GlobeNewsWire

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer...

6 months ago - GlobeNewsWire

The company announced positive results from a clinical trial.

6 months ago - The Motley Fool

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from th...

6 months ago - GlobeNewsWire

Investors are losing confidence because the company disappointed in a late-stage trial for the second time this week.

7 months ago - The Motley Fool

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an up...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with mo...

7 months ago - GlobeNewsWire

The company reported disappointing results from a late-stage clinical study.

7 months ago - The Motley Fool

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal yea...

Other stocks mentioned: AVXL, BNTX, LLY, VTVT
7 months ago - Benzinga

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the ...

7 months ago - GlobeNewsWire

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a cor...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - December 7, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) allegin...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - December 7, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limit...

7 months ago - Newsfile Corp

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast...

7 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 20...

7 months ago - Newsfile Corp

Biomarker Study Results Presented at the 62nd American Society of Hematology Annual Meeting Biomarker Study Results Presented at the 62nd American Society of Hematology Annual Meeting

7 months ago - GlobeNewsWire

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of its offic...

7 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusi...

7 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #Classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...

7 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast” or "the Company") (NASDAQ: MESO) and ce...

7 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - December 4, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limite...

7 months ago - Newsfile Corp

Investors with losses are encouraged to contact the firm before December 7, 2020; click here to submit trade information

7 months ago - GlobeNewsWire

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October...

7 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - December 3, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limit...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or "the ...

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - December 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limite...

7 months ago - Newsfile Corp

About MESO

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for adv... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Silviu Itescu
Employees
102
Stock Exchange
NASDAQ
Ticker Symbol
MESO
Full Company Profile

Financial Performance

In 2020, Mesoblast's revenue was $32.16 million, an increase of 92.30% compared to the previous year's $16.72 million. Losses were -$77.94 million, -13.21% less than in 2019.

Financial Statements